These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6622951)

  • 1. [Nuclear medicine therapy of bone metastases].
    Kimmig B; Hermann HJ; Kober B
    Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Internal radiation therapy for malignant neoplasm].
    Yokoyama K; Kinuya S; Tonami N
    Gan To Kagaku Ryoho; 1999 May; 26(6):768-74. PubMed ID: 10410145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sodium iodide 131I treatment of patients with skeletal metastases from differentiated thyroid carcinomas].
    Kusakabe K; Fukushima K; Ohta T; Maki M; Fujimoto Y; Yamazaki T
    Rinsho Hoshasen; 1987 Jul; 32(7):785-90. PubMed ID: 3682218
    [No Abstract]   [Full Text] [Related]  

  • 5. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress in radionuclide therapy].
    Kasagi K; Iwata M; Misaki T; Konishi J; Sakahara H
    Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
    Schlumberger M; Challeton C; De Vathaire F; Travagli JP; Gardet P; Lumbroso JD; Francese C; Fontaine F; Ricard M; Parmentier C
    J Nucl Med; 1996 Apr; 37(4):598-605. PubMed ID: 8691248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)].
    Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M
    Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396
    [No Abstract]   [Full Text] [Related]  

  • 12. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW; Xie P; Deng HF
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT; Davis LP
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F; Mognetti T; Resche I
    Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.